SANGUINE CORP. (SGNC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Dixie7777 who wrote (3684)	8/12/1998 12:31:00 PM
From: Profiteer	Read Replies (1) of 5402

Dixie 7777: If I recall, Prospector also posted info from the Dr. that Northfield requires actual outdated blood for their product. That, being in sort supply to begin with and taking into account only 50% of it would be consider useable for their product, I doubt that they could meet demand and be a serious competitor. The FDA itself considers real blood one of the most toxic based drugs available, with all it known disease carrying capability, not to mention unknown diseases in blood. The cost of cross-matching and typing (required with real blood products) would be way out of line compared to PHER-02. There are many more advantages of PHER-02 over " blood based" products if folks will go back and read through the information thread. Not sure I would consider this a threat to PHER-02

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next